K Pharma Dettes/EBITDA

Que fait K Pharma ? K Pharma Inc is a Japan-based pharmaceutical company headquartered in Minato-ku, Tokyo. The company operates in the Health Care sector, specifically within the Pharmaceuticals industry. It has a small team of 13 full-time employees. K Pharma Inc completed its initial public offering (IPO) on October 17, 2023, with the ticker symbol 4896.T and ISIN JP3280900006. The company's website is https://kpharma.co.jp/. K Pharma Inc focuses on the research, development, manufacture, and sale of pharmaceuticals. It is engaged in the field of induced pluripotent stem cell (iPS) drug discovery, which involves creating neural progenitor cells from iPS cells. These cells are cryopreserved and used in a treatment process where 200,000 cells are transplanted via injection into the spinal cord injury site of patients. The company also conducts research, development, manufacture, and sale of regenerative medicine products. K Pharma Inc operates through a single business segment, concentrating on pharmaceutical and regenerative medicine solutions. The company's activities are centered on developing innovative treatments, particularly in the area of spinal cord injury recovery using stem cell technology. K Pharma est l'une des entreprises les plus populaires sur Eulerpool.